4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Macular Degeneration by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 686 ongoing clinical trials involving Macular Degeneration
Of the 686 trials,345 trials are in Phase III
Furthermore, 133 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Macular Degeneration by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Macular Degeneration, an ophthalmology indication. Asia-pacific boasts of the highest number of ongoing clinical trials involving Macular Degeneration. North America and Europe are among some of the other prominent regions involved in Macular Degeneration-related drug trials.

Novartis AG: The leading ongoing Macular Degenerationrelated clinical trials sponsor

Novartis AG, the Switzerland-based healthcare company, is the top sponsor for Macular Degeneration-related ongoing clinical trials.

F. Hoffmann-La Roche Ltd, Bayer AG, RegenxBio Inc, and National Eye Institute are a few other notable sponsors involving Macular Degeneration. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Macular Degeneration

Aflibercept(Eylea), Ranibizumab (Lucentis, Patizra), Brolucizumab-dbll (Beovu, Vsiqq, Vizcu, Pagenax), Digitoxin and esculin (Augentropfen), and Pegaptanib sodium (Macugen, EYE001) are the key marketed drugs involving Macular Degeneration.     

Aflibercept (Eylea) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1, it functions through Placenta Growth Factor Inhibitor, and Vascular Endothelial Growth Factor an Inhibitor mechanism of action. Eylea is indicated for the treatment of Glaucoma and several other indications including Age Related Macular Degeneration, Choroidal Neovascularization, Macular Edema, Myopia, Diabetic Macular Edema, Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy (NPDR), Wet (Neovascular / Exudative) Macular Degeneration. The drug is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Regeneron Pharmaceuticals Inc, and Bayer AG. Aflibercept was first approved in 2011 and is formulated as an iso-osmotic injection solution for intravitreal route of administration.

Ranibizumab (Lucentis, Patizra) is a humanized monoclonal antibody fragment and a recombinant humanized IgO 1 isotype designed to bind to and inhibit vascular endothelial growth factor (VEGF-A), it functions via Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor mechanism of action. Ranibizumab is indicated for the treatment of Macular Degeneration and several other indications including choroidal Neovascularization, Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR), and Retinopathy Of Prematurity. The drug is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Genentech USA Inc, and Novartis. Ranibizumab was first approved in 2006 and is formulated as an injection for ophthalmic intravitreal use.